Government cancer experts say a drug from Roche has shown effectiveness as a new option to treat breast cancer before tumor-removing surgery.
The Food and Drug Administration panel voted 13-0, with one abstention, that the benefits of Perjeta as an initial treatment for breast cancer outweigh its risks. The recommendation is not binding, but could clear the way for the FDA to clear the drug as the first pharmaceutical option approved to shrink or eliminate cancerous tumors before surgery.
A study by Roche's Genentech unit showed women who received Perjeta as initial treatment were 18 percent more likely to be cancer-free after 12 weeks than women who received older drugs.
The FDA is considering granting Perjeta accelerated approval, a step reserved for promising drugs that have shown groundbreaking results.
Copyright 2013 Associated Press. All rights reserved.
Tuesday, April 20 2010 11:21 PM EDT2010-04-21 03:21:00 GMT
31 people are in trouble with the law after a three day prostitution sting in Richmond. Police told NBC12 they targeted specific areas where residents and business owners complained about the illegal activity.More >
While you were sleeping, the Internet never stopped… Here's what's trending today. ‘Exasperated' boy reacts to mom's pregnancy "What were you thinking? This makes no sense… This is exasperating!" AMore >
While you were sleeping, the Internet never stopped… Here's what's trending today.More >